Literature DB >> 3165437

Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.

F Stocchi1, S Ruggieri, A Antonini, F Baronti, G Brughitta, P Bellantuono, D Bravi, A Agnoli.   

Abstract

The continuous dopaminergic stimulation provided by infusion of dopamine agonist drugs, is a very effective strategy to control ON-OFF fluctuation in Parkinson's disease. Lisuride is a potent dopamine agonist drug, very soluble in water and can be administered subcutaneously. Many authors have shown that the subcutaneous infusion of lisuride can control fluctuations when applied in combination with oral levodopa as a 24 hour continuous infusion regimen. In this study, lisuride was given without any other antiparkinsonian medicament and using a 12 hour infusion regimen wherever possible. 13 fluctuating Parkinsonian patients were studied. 6 out of these 13 were satisfactory treated with lisuride alone and the remaining 7 with a combination of Lisuride + oral levodopa. Only in 3 out of 13 patients the 24 hour infusion regimen was required.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3165437     DOI: 10.1007/978-3-7091-8954-2_4

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  4 in total

1.  Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease.

Authors:  O K Sujith; Carol Lane
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

Review 2.  Classical dopamine agonists.

Authors:  R Horowski; P-A Löschmann
Journal:  J Neural Transm (Vienna)       Date:  2019-02-25       Impact factor: 3.575

Review 3.  Management of pain in Parkinson's disease.

Authors:  Munazza Sophie; Blair Ford
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

Review 4.  Optimising levodopa therapy for the management of Parkinson's disease.

Authors:  Fabrizio Stocchi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.